![Anti-CLEC9A [7H11]](https://cancertools.org/wp-content/uploads/5248ffe8-ef9a-45ce-a90b-5681eb6694f7.jpg)
Cat. #151706
Anti-CLEC9A [7H11]
Cat. #: 151706
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 3-4 weeks
Target: Mouse DNGR1
Class: Monoclonal
Application: ELISA ; FACS ; IF ; IP ; WB
Reactivity: Mouse
Host: Rat
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-CLEC9A [7H11]
- Alternate name: C-Type Lectin Domain Family 9 Member A; HEEE9341; UNQ9341; DNGR-1; CD37; DNGR1
- Research fields: Immunology;Stem cell biology
- Clone: 7H11
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Reactivity: Mouse
- Host: Rat
- Application: ELISA ; FACS ; IF ; IP ; WB
- Description: Recognises mouse DNGR-1, also known as CLEC9A, which is a highly specific marker of the CD8a+ and the CD103+ DC subsets, as well as a receptor able to recognise a preformed signal exposed on necrotic cells.
- Immunogen: RBL-2H3 cells expressing mouse DNGR-1 fused to an HA epitope
- Isotype: IgG1
- Myeloma used: Y3.AG.1.2.3
- Recommended controls: rat IgG1 isotype-matched control mAbs
Target Details
- Target: Mouse DNGR1
- Tissue cell line specificity: rat IgG1 isotype-matched control mAbs
- Target background: Recognises mouse DNGR-1, also known as CLEC9A, which is a highly specific marker of the CD8a+ and the CD103+ DC subsets, as well as a receptor able to recognise a preformed signal exposed on necrotic cells.
Applications
- Application: ELISA ; FACS ; IF ; IP ; WB
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Dry ice
References
- Joffre et al. 2010. Eur J Immunol. 40:1255-65. [PMID: 20333625]
- Sancho et al. 2008. J Clin Invest 118:2098-110 .[PMID: 18497879]
- Sancho et al. 2009. Nature. 458:899-903. [PMID: 19219027]
- Li et al. 2015. Eur J Immunol. 45(3):854-64. PMID: 25487143.
